Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:05:41.536Z.
Calculation as of: 2026-10-06T21:05:41.536Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fdfad12185ff1a6c55ef1236bc2340ccae7aa6e4dec3824b1e7761c8ffaeec30
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$2.06B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.06B
Price/FCF Ratio
N/A
TTM Avg
9.03
3Y Avg
8.56
5Y Avg
8.56
Market Cap
$2.05B
Price/FCF Ratio
41.31
TTM Avg
42.75
3Y Avg
385.34
5Y Avg
202.04
Market Cap
$2.11B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
Price/FCF Ratio
13.80
TTM Avg
17.53
3Y Avg
17.89
5Y Avg
19.30
Market Cap
$2.02B
Price/FCF Ratio
5.66
TTM Avg
22.88
3Y Avg
35.76
5Y Avg
35.76
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.08B | N/A | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 9.03 | 8.56 | 8.56 |
| Vericel Corporation (VCEL)vs › | $2.05B | 41.31 | 42.75 | 385.34 | 202.04 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 13.80 | 17.53 | 17.89 | 19.30 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 9.31 | 10.72 | 12.71 | 64.86 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 5.66 | 22.88 | 35.76 | 35.76 |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A | 1575.22 | 1575.22 | 1575.22 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
